Efficacy looks better with daraxonrasib plus chemo versus monotherapy, but toxicity looms.
ApexOnco Front Page
Recent articles
Inlexzo gets the nod in BCG-unresponsive non-muscle invasive bladder cancer, but the group has bigger plans.
The company highlights the safety of its KLK2-targeting T-cell engager pasritamig.
As patritumab-dxd's problems mount, Astra's decision to say no to this project looks smart.
But camizestrant’s use could depend on uptake of monitoring – for now.
Gilead’s TROP2 ADC sets the bar for Astra/Daiichi’s Datroway in first-line TNBC.
Any hopes of differentiation could come down to side effects.
Early data on SSGJ-707 in PD-L1-positive lung cancer spur comparisons against ivonescimab.
